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Abstract
Joint cartilage is attacked in both autoimmune inflammatory and
osteoarthritic processes. Type IX collagen (CIX) is a protein of
importance for cartilage integrity and stability. In this study we
have backcrossed a transgenic disruption of the col9a1 gene,
which leads to an absence of CIX, into two different inbred
mouse strains, DBA/1 and B10.Q. None of the CIX-deficient
mice developed observable clinical or microscopic
osteoarthritis, but DBA/1 male mice had more pronounced
enthesopathic arthritis, the so-called stress-induced arthritis.
Both DBA/1 and B10.Q strains are susceptible to the induction
of collagen-induced arthritis, and CIX deficiency in both strains
led to the development of a more severe arthritis than in the
controls. Induction of arthritis with monoclonal antibodies
against type II collagen (CII) led to an earlier arthritis in the paws
that also involved the knee joints. The antibodies used, which
were specific for the J1 and the C1I epitopes of CII, initiate their
arthritogenic attack by binding to cartilage. The C1I-specific
antibodies bound to cartilage better in CIX-deficient mice than
in wild-type animals, demonstrating that the lack of CIX in
cartilage leads to an increased accessibility of structures for
antibody binding and thus making the joints more vulnerable to
inflammatory attack. These findings accentuate the importance
of cartilage stability; cartilage disrupted as a result of genetic
disorders could be more accessible and vulnerable to an
autoimmune attack by pathogenic antibodies.
Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are both
degenerative diseases of the joint and affect articular cartilage,
synovium and bone with a loss of function and joint deformity.
RA is, however, an inflammatory disease that involves a joint-
specific autoimmune attack. Collagen type IX (CIX) is a protein
associated with hyaline cartilage, together with collagen type
II (CII) and XI (CXI). The triple helix of CIX is composed of three
genetically distinct polypeptide-chains and belongs to the
group of fibril-associated collagens with interrupted triple hel-
ices (FACIT). CIX molecules cover the surface of the hetero-
typic fibril of CII/CXI in a periodic fashion. Covalent cross-links
between CII and CIX as well between other CIX molecules are
formed [1-3], suggesting that CIX might form a macromolecu-
lar bridge between fibrils and with other matrix constituents,
compromising the stiffness and tensile strength of cartilage
[4]. Evidence for such a role comes from studies of transgenic
mice with a truncated form [5] or complete deletion of the
α1(IX) chain, leading to an absence of CIX in the cartilage [6].
Both types of mice have been reported to develop a mild form
of OA in the knees. In addition, the importance of CIX was
highlighted when a form of multiple epiphyseal dysplasia,
EDM2, was linked to the col9a2 gene [7,8]. These patients
developed irregular epiphyses with a gradual appearance of
OA in the knees. Taken together, these observations suggest
that CIX is important in maintaining the long-term stability of
the articular cartilage.
The most widely used animal model for arthritis is collagen-
induced arthritis (CIA), which has a disease course similar to
that of RA, both in the spread of affected joints and in his-
topathological findings. CIA has a strong B-cell response, pro-
ducing antibodies directed toward CII-specific structures
[9,10], and these antibodies have been shown to be
CAIA = collagen-antibody-induced arthritis; CII = type II collagen; CIX = type IX collagen; CIA = collagen-induced arthritis; COMP = cartilage oligo-
meric matrix protein; ELISA = enzyme-linked immunosorbent assay; IFN = interferon; OA = osteoarthritis; PBS = phosphate-buffered saline; PCR = 
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pathogenic in passive transfer experiments [11-15]. CII-spe-
cific T cells promoted the arthritis initiated by these antibodies
[16-18]. A requirement for T cells in CIA was demonstrated by
using anti-CD4 [19] or anti-TCRαβ [20] monoclonal antibod-
ies and T-cell-deficient mice [21]. However, T cells alone can-
not explain the pathology in CIA; hence both humoral immunity
and cellular immunity were found to be absolutely essential
[17]. Similarly, it is also possible to study arthritogenic path-
ways by using animal models other than CIA to pinpoint the
effect of different disorders and thereby fine-tune the under-
standing of the underlying mechanisms of RA. Such models
are collagen-antibody-induced arthritis (CAIA) and stress-
induced arthritis (SIA).
In CAIA it is possible to study the inflammatory phase of the
immune response without involving the primary phase by acti-
vating a cascade of reactions involving complement [22] and
Fcγ receptors [23]. Neutrophils and macrophages are the
major mediators of this inflammation [12]. CAIA is also capa-
ble of initiating arthritis independently of T and B cells, actually
in the absence of either T or B cells, but not both enhanced
the disease, arguing for a regulative role for these cells [16].
SIA is a spontaneous arthritis occurring in old male DBA/1
mice that are grouped from different litters. Macroscopically, it
is similar to CIA, with edema and deformity of the hindpaws;
however, SIA is primarily an enthesopathy characterized by the
proliferation of fibroblasts and the formation of periarticular
enthesophytes of cartilage and bone that can result in marginal
ankylosis. In contrast to CIA, SIA is T-cell independent and
shows minimal proliferative synovitis, without involving large
cellular infiltrates [24].
Ankylosing enthesitis is a pathological feature in a group of
chronic arthritides known as spondylarthropathies, with the
same inflammatory mediators as in RA. IFN-γ (secreted proba-
bly by the innate immune system involving IFN-γ producing
cells such as natural killer and myeloid cells) was shown to
promote SIA [25]. It has been well documented that bone mor-
phogenetic protein (BMP), a member of the transforming
growth factor (TGF) superfamily, is involved in endochondral
bone formation. Recently, an antagonist to BMP was shown to
inhibit the onset and progression of SIA [26]; however, TGF-
β1 injected directly into the knees induced enthesopathies
[27]. The causative factor of spondylarthropathies is believed
to be an endocrine disorder in humans [28] and might also be
a compensatory mechanism of joint instability, supported by
the stabilization process of osteoarthritic knees [29].
This study was designed to address whether the development
of autoimmune arthritis as in RA might be dependent on carti-
lage quality. To address this question we used CIX mutant
mice lacking the α1 (IX) chain [6] and assumed that this
mouse might be more susceptible to inflammatory arthritis
because of mild cartilage matrix destabilization. The data pre-
sented here confirmed our hypothesis that these mice devel-
oped a more severe arthritis in CIA and CAIA, which could be
explained by an enhanced accessibility of CII-specific antibod-
ies to cartilage. We also found that this mouse was more
prone to developing enthesopathy but we could not reproduce
earlier findings that the CIX deficiency leads to OA.
Materials and methods
Animals
The transgenic mice harboring mutant col9a1  have been
described previously [6]; in brief, exon 8 of col9a1 was dis-
rupted by inserting a phosphoglycerate kinase 1 (pgk-1) pro-
moter-neomycin gene cassette. Homozygous mutant mice
lacked both mRNA and polypeptide, but even though col9a2
and col9a3 transcription was normal the polypeptides were
not detectable in cartilage. The CIX-deficient mice, denoted
C9T, were then backcrossed to B10.Q/Rhd (originally from
Jan Klein, Tübingen, Germany) and DBA/1/Rhd (originally
from Jackson laboratories Inc., Bar Harbor, ME, USA) animals.
Rhd indicates that these classical inbred mouse strains have
been maintained in our laboratory for more than two decades.
The two lines were further denoted by the suffixes -BQ and -
DQ, to indicate B10.Q and DBA/1 backgrounds, respectively.
The mice were backcrossed for 10 or 11 generations and the
remaining fragment was analyzed with microsatellite markers
between positions 6.5 and 43.1 centimorgans on chromo-
some 1 (see Figure 1 below). SinceC9T-BQ was determined
as being free from genetic contamination, this line was kept by
intercrossed breeding, and B10.Q animals were used as con-
trols in the experiments.
All mice were kept in a climate-controlled environment with 12
hours light/12 hours dark cycles, housed in polystyrene cages
containing wood shavings, standard rodent chow and water
ad libitum in the Animal Department of Medical Inflammation
Research in Lund, Sweden. All experiments were performed
on age-matched mice, between 8 and 16 weeks of age. The
Lund-Malmö laboratory animal ethical committee approved the
animal experiments described in this article.
Screening
Genomic DNA was prepared from the tip of tail or toe [30].
Transgenic mice were screened by PCR with primer pairs spe-
cific for the NeoR gene within the construct. Wild-type animals
were determined by using another primer pair inside the
Col9a1 gene that flanked the construct, yielding an incom-
plete product without amplification if the construct was
present. Both primer pairs were run simultaneously for each
sample during PCR, to yield on agarose gel electrophoresis
two different products from each pair, depending on the
haplotype.Available online http://arthritis-research.com/content/8/4/R102
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Induction and evaluation of arthritis
CIA
Mice were immunized intradermally at the base of the tail with
50 or 100 µg of CII, prepared from Swarm rat chondrosar-
coma. All dosages were emulsified with complete Freund's
adjuvant (Difco, Detroit, IL, USA) in a total volume of 100 µl. In
early experiments, arthritis was followed by using the original,
referred to as the simple, macroscopic score system for the
four paws ranging from 1 to 3: 1 = swelling or redness in one
joint or toe; 2 = more than one joint/toe or the ankle affected;
3 = severe arthritis in the entire paw. During later experiments
the scoring protocol was improved and animals were scored
by the system ranging from 0 to 15 per paw [31], referred to
as the extended protocol. For comparison, scores used with
the extended system have been converted from original docu-
ments for each individual and day in accordance with the fol-
lowing relation between extended and simple: 1 = 1, 2 to 10
= 2, and 11 to 15 = 3.
SIA
Spontaneous development of arthritis is influenced by hormo-
nal and behavioral factors [32]. It has been stressed that the
number of mice is critical (at least three), and grouping should
be from sexually mature mice from different litters for the induc-
tion of SIA. Selection was used randomly to reduce cage var-
iations. Arthritis was assessed as described above.
CAIA
To induce arthritis with anti-CII antibodies, GammaBind™ Plus
Sepharose™ column (Amersham Biosciences, Uppsala, Swe-
den) purified IgG from the culture supernatants of B-cell hybri-
domas CIIC1 (C1I epitope) and M2139 (J1 epitope) [33-35]
were solubilized in PBS, sterile filtered and injected intrave-
nously [12]. Each antibody (4.5 mg) was given as a cocktail on
two occasions in a total volume of 400 µl. On day 5, 50 µg of
lipopolysaccharide per mouse was injected intraperitoneally
into all mice. Arthritis was assessed as described above.
ELISA
ELISA was performed with sera obtained at day 35 from mice
through retro-orbital plexus bleeding. Microtiter plates (Immu-
nolon 2 HB; Thermo Labsystems, Franklin, MA, USA) were
used, otherwise the protocol was followed as described else-
where [36].
Histology
CIIC1 (C1I epitope, ARGLT), M2139 (J1 epitope, MPGER-
GAAGIAGPK), CIIC2 (D3 epitope, ARGAQGPPGATGFP),
CIIF4 (F4 epitope, ERGLKGHRGFT) and CIIE8 (E8 epitope,
LAGQRGIV) antibodies were biotinylated as described previ-
ously [33]; 100 µg of antibodies in 100 µl of PBS was then
injected intraperitoneally into 1-day-old mice [37]. The mice
were decapitated a day later and the hindlimbs were immedi-
ately embedded in OCT compound (Sakura Finetek, Zoeter-
woude, The Netherlands), snap-frozen in isopentane and kept
frozen at -70°C until cryosectioning. Staining was performed
as described previously [38].
Calculation of antibody binding
Sections were selected from the ankle region with homoge-
nous, whole, round parts and from the same joint part as pos-
sible. All pictures were taken on the same occasion and stored
as high-grade TIFF files, with SPOT advanced WIN v. 4.1 soft-
ware (Digital Instruments Inc., Sterling Heights, MI, USA). All
image analyses were performed at the same time with Easy
Image Analysis 2000 v. 2.7.1.3 (Tekno Optik AB, Huddinge,
Sweden) with threshold levels set as specifically as feasible
and used unchanged throughout the analysis. The total area
was marked manually and the software marked the stained
area. The software calculated the stained area as a percent-
age of the total.
Statistics
All ELISA data were first log-transformed and then used for
calculations of the mean and an independent-samples t test,
except for SD. Mean ELISA values are expressed as the anti-
Figure 1
Genetic map of chromosome 1 around the col9a1 gene Genetic map of chromosome 1 around the col9a1 gene. Shown is a 
map of the genotyped chromosome 1 from 10th and 11th generations 
of mice backcrossed to B10.Q (C9T-BQ) and DBA/1 (C9T-DQ) 
strains, indicating the markers used and the position of col9a1. Chro-
mosomal length and intermarker distances are proportional to the 
graphic length. The vertical bars specify background inheritance with 
C57bl mice (black bars), DBA/1 mice (grey bars) and 129 mice 
(hatched bars); linked markers and intermarker borders (striped bars) 
are also indicated.Arthritis Research & Therapy    Vol 8 No 4    Carlsen et al.
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log of transformed mean data (geo-mean). The Mann-Whitney
U ranking test was used for score and one-way analysis of var-
iance for onset. Pearson χ2 with Yates's correction was calcu-
lated for incidence, or Fisher's exact test if groups were of less
than five. In antibody-binding studies an independent-samples
t test was used.
Results
Increased susceptibility to stress-induced arthritis but 
not osteoarthritis in CIX-deficient mice
To evaluate the susceptibility to arthritis in genetically pure
inbred strains, the C9T mice were backcrossed into B10.Q
and DBA/1 genetic backgrounds. These mouse strains
express the MHC Aq class II gene, permitting susceptibility to
CIA. In addition, DBA/1 males develop a spontaneous
enthesopathy, denoted SIA, which readily develops after
males are grouped together from different litters. The C9T
mice were derived from a 129/sv line and were backcrossed
for more than 10 generations followed by intercrossing and
selection for minimal linked fragments, leaving a defined frag-
ment around the col9a1 gene (Figure 1). C9T-BQ had a mini-
mal 129-derived congenic fragment, whereas C9T-DQ had a
larger congenic fragment that also contained DNA derived
from both C57BL and 129 lines. The C57BL positive marker
within C9T-DQ most probably originated from C57BL/6,
which was used during transmission to a germline and then
backcrossed with 129/sv to an inbred line [6]. Another embry-
onic stem 129 cell line, D3 [39], was used for electroporation
but could not be distinguished from 129/sv by the microsatel-
lite markers used. These strains seemed to have normal knee
joints, because we did not find any microscopic or macro-
scopic sign of OA or other pathology in a large number of nor-
mal young and old (more than one year) mice of either strain.
Samples were also taken from CIA and SIA experiments with
littermate controls of both heterozygous and wild-type haplo-
types, with additional inbred DBA/1 and B10.Q strains for
negative comparison (data not shown).
To investigate whether the CIX-deficient mice were more
prone to SIA, the males from different litters were grouped and
followed for the development of arthritis. The disease typically
started with swelling and erythema in the hind ankle and toes,
which lasted for about ten weeks and then subsided leaving
the joints deformed and stiff. Relapses were commonly seen
after the deformity at periodic intervals. The CIX-deficient mice
had a more severe disease than the wild-type or heterozygote
controls (Table 1).
Table 1
Summary of experiments conducted on C9T mice
Arthritic/total Simple maximal Extended 
maximal
Anti-CII 
antibody
Experiment Strain Group (n/n) Day of onset arthritic score arthritic score titer (µg/ml)
CIAa C9T-DQ Homozygous 5/11 60.6 ± 39.1 8.6 ± 2.7e nd 371.7 ± 359.3
CIAa C9T-DQ Heterozygous 9/17 50.9 ± 8.2 5.4 ± 2.0e nd 532.1 ± 529.2
CIAa C9T-DQ Wild type 10/17 55.6 ± 19.0 5.1 ± 2.9e nd 454.3 ± 489.0
CIAb C9T-BQ Homozygous 6/9 62.8 ± 13.6 8.3 ± 2.0 29.9 ± 15.3e nd
CIAb B10.Q Wild type 5/9 66.4 ± 17.3 6.0 ± 2.3 23.8 ± 8.2e nd
SIAc C9T-DQ Homozygous 9/18 44.3 ± 18.4 3.1 ± 1.2f nd nd
SIAc C9T-DQ Heterozygous 19/26 43.7 ± 30.1 2.7 ± 1.6f nd nd
SIAc C9T-DQ Wild type 12/17 39.2 ± 23.8 2.0 ± 0.9f nd nd
CAIAd C9T-BQ Homozygous 
Ab
13/20 5.5 ± 3.0g 4.8 ± 2.8 12.8 ± 11.2 nd
CAIAd C9T-BQ Homozygous 
PBS
0 / 8 --- n d
CAIAd B10.Q Wild-type Ab 5/8 8.4 ± 0.5g 5.6 ± 3.0 11.2 ± 8.5 nd
Where errors are shown, results are means ± SD. aOne generation intercrossed C9T-DQ and littermate control females were immunized with 50 
µg of CII. bPure lines of C9T-BQ and B10.Q male mice were immunized with 100 µg of CII. cOne generation intercrossed male C9T-DQ and 
littermate controls were randomly and pooled blind. dAnti-CII antibody-induced arthritis on pure line of male C9T-BQ (homozygous Ab) and male 
B10.Q (wild-type Ab), and controls injected with PBS (homozygous PBS). eHomozygous mice were significantly higher in score (p < 0.05) than 
both heterozygous (if present) and wild type, respectively. There were no other significant differences between the groups within the experiments. 
fHomozygous mice were significantly higher in score (p = 0.025) than wild type but not heterozygous. There were no other significant differences 
between the groups. gHomozygous mice that received Ab had a significantly earlier onset (p = 0.035) with six arthritic mice before 
lipopolysaccharide injection, than their wild-type counterpart. Two homozygous mice injected with Ab also developed knee inflammation at days 4 
and 6, which were not seen in wild-type Ab. CAIA, collagen-antibody-induced arthritis; CIA, collagen-induced arthritis; CII, type II collagen; nd, not 
determined; SIA = stress-induced arthritis.Available online http://arthritis-research.com/content/8/4/R102
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Severity of collagen-induced arthritis is increased in CIX-
deficient mice
To test whether the CIX deficiency makes the cartilage more
susceptible to autoimmune-mediated inflammation, we immu-
nized the mice with heterologou s  r a t  C I I.  D B A/ 1  m i ce  a r e
highly susceptible to CIA, and to avoid a possible influence of
SIA we used only females. B10.Q mice are less susceptible to
arthritis and hence only males were tested with a higher CII
dosage. DBA/1 mice with CIX deficiency developed signifi-
cantly more severe arthritis than the heterozygous or wild-type
littermate controls (Table 1 and Figure 2). C9T-BQ animals
also had significantly more severe arthritis than the wild type.
The increase in severity was observed early after the onset and
lasted until the arthritis in both the strains had subsided. The
autoimmune response was not affected, because no differ-
ence in serum levels of antibodies against CII was observed in
either C9T-DQ (Table 1) or in an early low-dosage experiment
in C9T-BQ with 50 µg/ml CII (homozygous, 109.5 ± 129.2
µg/ml; heterozygous, 96.0 ± 98.7 µg/ml; wild type, 135.5 ±
230.4 µg/ml; means ± SD). These findings argue in favor of
our hypothesis that CIX deficiency might regulate arthritis
through greater exposure of the cartilage to inflammatory
attack. To test this possibility we conducted passive transfer
experiments with CII-specific arthritogenic antibodies.
CIX-deficient B10.Q mice developed a more severe 
collagen-antibody-induced arthritis
To induce CAIA we used two well-defined monoclonal anti-
bodies, CIIC1 and M2139. CIX-deficient B10.Q mice devel-
oped arthritis earlier (even before lipopolysaccharide injection)
than the control group (Figure 3). After lipopolysaccharide
injection, both groups developed arthritis with a peak at about
day 10 and subsided at the same rate. Interestingly, some CIX-
deficient mice had signs of arthritis in the knees (Table 1). This
could be seen as gait disturbances as well as swelling and ery-
thema of the knees. Comparable observations were observed
in C9T-DQ mice, in which four out of nine mice developed
knee inflammation after disease progression in the paws dur-
ing onset and subsidence (data not shown).
Anti-CII antibodies bind more efficiently to cartilage 
lacking CIX
It is possible that the deficiency of CIX might not only destabi-
lize cartilage but could also affect the exposure of epitopes for
antibody binding. To test this possibility, biotinylated mono-
clonal antibodies against the major B-cell epitopes of CII (C1,
J1, C2, F4 and E8) were injected into newborn mice. In this
screen there was an indication that the CIIC1 antibody could
bind better to the cartilage from CIX-deficient mice than to that
from controls. We extended this observation with a larger
number of mice. We quantified the CIIC1 binding by develop-
ing a method in which both density and area could be meas-
ured objectively (Table 2 and Figure 4). Using this method, we
showed that the CIIC1 monoclonal antibody had a denser
staining of a larger area in CIX-deficient mice than in controls.
Discussion
CIX-deficient mice have a subtle defect of the cartilage, which
is here indicated by their higher susceptibility to developing
spontaneous enthesopathic arthritis. Interestingly, these mice
also developed a more severe autoimmune arthritis, as shown
with the CIA model. Parts of this effect could be explained by
the higher accessibility of CIX-deficient cartilage for binding of
arthritogenic CII-specific antibodies.
CIX-deficient mice [6] have previously been shown to develop
microscopic OA at one year of age, with loss of cartilage at the
femoral and tibial joint surfaces and increased cartilage and
bone formation at the periphery, leading to prominent shape
changes. In transgenic mice with truncated CIX [5], OA was
Figure 2
Severity of collagen-induced arthritis is increased in mice deficient in  collagen type IX Severity of collagen-induced arthritis is increased in mice deficient in 
collagen type IX. The figure shows a comparison of arthritis develop-
ment between littermate females of C9T-DQ from the intercrossed 
DBA/1 line, as in Table 1. Mean scores were calculated on arthritic ani-
mals. An asterisk indicates a significant difference (p < 0.05) between 
the homozygous group and the control groups (heterozygous and wild 
types).
Figure 3
B10.Q mice deficient in collagen type IX developed a more severe col- lagen-antibody-induced arthritis B10.Q mice deficient in collagen type IX developed a more severe col-
lagen-antibody-induced arthritis. Arthritis development was followed in 
C9T-BQ and B10.Q mice injected with anti-collagen type II antibody, 
as in Table 1. Mean scores were calculated on arthritic animals.Arthritis Research & Therapy    Vol 8 No 4    Carlsen et al.
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observed in mice up to one year old as a decreased intensity
of Safranin O staining and roughening or erosion of the artic-
ular surface. In our study we could not detect either gait prob-
lems or histological OA. One reason for this might have been
that we focused on mice with the CIX deficiency backcrossed
to DBA/1 and B10.Q genetic backgrounds, which are not
known to be sensitive for spontaneous OA, unlike the C57BL/
6 and BALB/c [40] genetic backgrounds used in the previous
studies. The development of spontaneous enthesopathy in
DBA/1 mice is an indication of the presence of a good com-
pensatory mechanism to preserve joint homeostasis [29],
resulting in an improved repair mechanism for local injury [41].
However, enthesopathy in DBA/1 mice is a pathological event,
with increased new bone formation in tissues where tendons
and ligament attach, with abundant proliferative fibroblasts
and chondrocytes. In our SIA experiments the homozygous
mice developed a more severe disease, which suggests that
the mediators released during stress affect chondrocytes pro-
foundly, and chondrocytes might possibly try to compensate
for the CIX deficiency by the overexpression of cartilage
components.
To test our hypothesis about whether cartilage disorder could
alter the course of arthritis as a result of enhanced accessibility
to the immune system, we used our CIX-deficient mice in two
different genetic backgrounds in CIA. In both these back-
grounds a more severe development of arthritis was observed
with CIX deficiency. This phenomenon could not be explained
by increased turnover of the fragile matrix and, in turn, priming
of autoreactive T cells or efficient tolerance induction, because
the disease course was as self-limiting as in the controls. Sim-
ilarly, there was no change in antibody titers, which argues
against de novo priming of T cells. Still, there might have been
a difference in the accessibility of cartilage to antibodies,
because antibodies are shown to bind complement and to be
involved in direct cell interactions via Fc receptors, which
would certainly have an effect on disease progression. In fact,
this was the case when tested with direct CII antibody injec-
tion: homozygous mutant mice developed arthritis much earlier
than the controls and had more antibodies attached to the car-
tilage. This also ruled out the possibility of T-cells as the main
promoter during the course of arthritic disease in this model,
because antibody-mediated arthritis is T-cell independent.
Because CAIA experiments gave such a rapid response and
also an apparent knee inflammation in both the mouse strains,
we were prompted to perform in vivo binding studies with dif-
ferent monoclonal antibodies. Of the different antibodies used,
CIIC1 binding to the C1I epitope showed an increased binding
to cartilage. The C1 epitope was identified as a major epitope
in generating the antibody response to CII, and the various
antibodies thus developed recognized different parts of the
epitope: the C1I epitope 359 to 363, the C1II epitope 359 to
366 and the C1III epitope 359 to 369 [35]. However, all anti-
bodies are dependent on the first part of the epitope, where
the CIIC1 antibody binds. The antibody response to the C1
epitope dominates the immune response in CIA in both mice
[42] and rats [43].
The CIIC1 antibodies also impaired cartilage formation by cul-
tured chondrocytes [44], strongly inhibited the self-assembly
of CII in vitro [45] and caused disorganization of CII fibrils in
the extracellular matrix without affecting chondrocyte morphol-
ogy, along with increased matrix synthesis [46], and thus the
antibodies directed to this epitope can contribute directly to
cartilage destruction. Increased binding of CIIC1 to the CIX-
deficient cartilage indicates that the C1I  epitope is more
exposed for the CIIC1 antibody in the absence of CIX and
more antibodies bind per CII molecule in the deeper layers of
cartilage.
Interestingly, antibodies against the C1 epitope have also
been shown to be associated with RA [47]. Clearly, the C1
epitope is not only important for its immunodominance but also
contributes to matrix component interactions, signaling and
stability. In contrast, murine antibodies reacting to the F4
epitope were not arthritogenic in CAIA and were associated
with OA rather then RA [47]. Furthermore EDM1, another sub-
group of multiple epiphyseal dysplasia, and pseudochondro-
plasia are linked to defects in cartilage oligomeric matrix
protein (COMP) [48] and share pathogenesis with EDM2
[49], suggesting that COMP and CIX are interacting in the
large polymeric network of cartilage. Deficiency of CIX might
therefore also lead to instability and changed exposure of
Figure 4
Improved binding of anti-collagen type II antibodies to cartilage defi- cient in collagen type IX Improved binding of anti-collagen type II antibodies to cartilage defi-
cient in collagen type IX. Examples of immunohistochemical staining of 
the ankle from the hind paws of newborn mice, injected intraperito-
neally with 100 µg of biotinylated C1 antibodies, as described in the 
Materials and methods section. Pictures show the tibia to the far left 
and the talus and calcaneus to the far right. (a) Section from a B10.Q 
mouse; (b) the same area from a C9T-BQ mouse except that the tibia 
is out of the picture. In this example the calcaneus was used for calcula-
tions. The pictures were developed and handled identically.Available online http://arthritis-research.com/content/8/4/R102
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COMP. Increased serum levels of COMP have not been
detected in different human OA, but it would be interesting to
study COMP-mediated pathology in CIX-deficient mice.
Using CIX-deficient mice of two well-defined mouse inbred
lines B10.Q and DBA/1, which are susceptible to CIA, we
have tested the possibility that disordered cartilage alters sus-
ceptibility to autoimmune arthritis. We found that the lack of
CIX increased the binding of antibodies to the major epitopes
on CII in cartilage and led to a higher susceptibility to both CIA
and CAIA. RA probably represents a wide variety of diseases
with different initiation events. It could in fact include sub-
groups that have a mild cartilage defect genetically. Such
groups could be dormant but the presence of fragile cartilage
could expose B-cell epitopes to binding of autoreactive anti-
bodies. The bound antibodies could then initiates an inflamma-
tion with the release of cartilage antigens, thereby further
driving an autoimmune attack towards cartilage proteins. This
study supports the idea that a mild disruption to cartilage
increases the severity of arthritis.
Conclusion
To understand the importance of CIX for cartilage integrity and
stability and in the disease process of arthritis, we used a
transgenic disruption of the col9a1  gene, leading to an
absence of CIX, in two different genetic backgrounds (DBA/1
and B10.Q). None of the CIX-deficient mice developed OA,
but the control DBA/1 male mice had more pronounced
enthesopathic arthritis. Both DBA/1 and B10.Q strains are
susceptible to the induction of CIA, and CIX deficiency in both
strains led to the development of a more severe arthritis than
in the controls. Induction of arthritis with monoclonal antibod-
ies against CII led to earlier arthritis in the paws and also
involved the knee joints. The C1I-specific antibodies bound to
cartilage better in CIX-deficient mice than in wild type animals.
This finding demonstrates that a lack of CIX in cartilage leads
to an increased accessibility of structures for antibody binding
and thus makes the joints more vulnerable to an inflammatory
attack. These observations accentuate the importance of car-
tilage stability; disrupted cartilage due to genetic disorders
might be more accessible and vulnerable to autoimmune
attack by pathogenic antibodies.
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